Enthesitis-related arthritis (ERA), is characterized by the involvement of the entheses and the axial skeleton along with peripheral joints. The juvenile ERA is the most common cause of acquired disability and reduced the health-related quality of life in childhood. However, recently the use of anti-tumor necrosis factor (TNF) agents within the first year of diagnosis have been associated with benefits in several clinically significant outcomes.
Therapeutic options for ERA, which are primarily based on adult studies, include monotherapy or combination therapy with non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and other biological agents. In a recent study, the effects of anti-TNF therapy and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) were analyzed on several ERA-related outcomes, including active joint and…
